Peptide Market Trend: Glucagon & Glycogen Research Data Insights
Title: Peptide Market Trend: Glucagon & Glycogen Research Data Insights Abstract: Recent peptide market data (2023–2025) reveals glucagon and glycogen research driving a 12.4% CAGR in therapeutic peptides. Glucagon analogs (e.g., Dasiglucagon) show 98% purity vs. traditional injectables, offering rapid hypoglycemia reversal but higher cost. Glycogen-targeting peptides (e.g., GLP-1 hybrids) expand metabolic disease applications. Brand comparison: Novo Nordisk’s patented glucagon leads in efficacy (t½ 45 min), while generic Chinese factories (e.g., Hybio) offer 40% lower pricing with GMP/FDA certificates. Key selection criteria: purity (>95%), endotoxin levels (<0.5 EU/mg), and cold-chain logistics (2–8°C). Industry trends favor oral delivery systems, reducing injection burden.